Context Therapeutics (NASDAQ:CNTX) Coverage Initiated at JMP Securities

JMP Securities initiated coverage on shares of Context Therapeutics (NASDAQ:CNTX) in a research report sent to investors on Wednesday morning, Marketbeat.com reports. The brokerage issued an outperform rating and a $4.00 price objective on the stock.

A number of other equities analysts have also recently weighed in on CNTX. D. Boral Capital assumed coverage on shares of Context Therapeutics in a research note on Monday, November 25th. They set a “buy” rating and a $9.00 price target on the stock. HC Wainwright restated a “buy” rating and set a $6.00 target price on shares of Context Therapeutics in a research report on Monday, September 23rd. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $6.33.

Context Therapeutics Stock Up 11.0 %

NASDAQ CNTX opened at $1.21 on Wednesday. The stock has a market capitalization of $90.75 million, a P/E ratio of -1.33 and a beta of 2.10. Context Therapeutics has a 52-week low of $0.89 and a 52-week high of $2.75. The firm has a 50-day moving average price of $1.52 and a 200 day moving average price of $1.94.

Context Therapeutics (NASDAQ:CNTX) last issued its earnings results on Wednesday, November 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.11). On average, equities research analysts expect that Context Therapeutics will post -0.51 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Context Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Driehaus Capital Management LLC purchased a new position in shares of Context Therapeutics during the 2nd quarter worth approximately $4,527,000. Great Point Partners LLC purchased a new position in Context Therapeutics during the second quarter worth $14,876,000. Blue Owl Capital Holdings LP acquired a new position in shares of Context Therapeutics in the second quarter worth $10,348,000. State Street Corp lifted its position in shares of Context Therapeutics by 21.5% in the third quarter. State Street Corp now owns 111,907 shares of the company’s stock valued at $219,000 after acquiring an additional 19,800 shares in the last quarter. Finally, Nantahala Capital Management LLC purchased a new stake in Context Therapeutics during the 2nd quarter worth about $3,881,000. Institutional investors and hedge funds own 14.03% of the company’s stock.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.